ERAS as of Oct 31 · 18:54 ET
ERASNasdaqPharmaceutical Preparations
Erasca, Inc. · Brief
Next report
11 days
Nov 11 · after closeest.Q3 FY26
Expected move
No implied move.
0 of 8≥ implied
- avg implied
- ±32.2%
- avg realized
- ±3.4%
Mar 20 '25±85.0%▲+3.38%×0.04
May 13 '25±16.4%▼−4.51%×0.27
Aug 12 '25±85.0%▲+3.85%×0.05
Q3 FY25±18.7%▼−4.15%×0.22
Jan 20 '26±19.7%▲+2.45%×0.12
Q1 FY26±11.1%▼−7.03%×0.63
May 11 '26±8.4%▼−0.57%×0.07
Q2 FY26±13.2%▲+1.47%×0.11
quarterimplied−85%0+85%realized×
Q2 FY26±13.2%▲+1.47%×0.11
May '26±8.4%▼−0.57%×0.07
Q1 FY26±11.1%▼−7.03%×0.63
Jan '26±19.7%▲+2.45%×0.12
Q3 FY25±18.7%▼−4.15%×0.22
Aug '25±85.0%▲+3.85%×0.05
2 older reports
May '25±16.4%▼−4.51%×0.27
Mar '25±85.0%▲+3.38%×0.04
Shaded = implied · tick ▲▼ = realized · × = |realized| ÷ impliedSource: options EOD · implied at prior close · realized close to close
Bull & bear
Nov 11 report · est.Bull2 of 3
Bear2
AI captions · Sep 28 '26once per report · top 2 per case
Linked exposure
ERAS report sessionNo linked exposure.
Your note
privateThesis 0 · Decisions 0 · Observations 0
No thesis.